MétaCan
Menu
← Retour à la cohorte
Enregistrement W4417012043 · doi:10.1182/blood-2025-1581

Trial in progress: nutrition and exercise to optimize muscle and adiposity in adolescents and young adults with B-cell acute lymphocytic leukemia: The neoma ALL trial

2025· article· en· W4417012043 sur OpenAlexaff
Samuel J. Yates, Lauren Miller, Suzanne Massarani, John Cursio, Nicholas Feinberg, Cassandra Kuissi, Karteek Popuri, Mirza Faisal Beg, Varun Akella, Brandon Faubert, W Stock

Notice bibliographique

RevueBlood · 2025
Typearticle
Langueen
DomaineMedicine
ThématiqueChildhood Cancer Survivors' Quality of Life
Établissements canadiensSimon Fraser UniversityMemorial University of Newfoundland
Organismes subventionnairesnon disponible
Mots-clésYoung adultObesityClinical trialAcute lymphocytic leukemiaMetabolic syndromeRandomized controlled trial

Résumé

récupéré en direct d'OpenAlex

Abstract Background and Significance: In 2021-2023, 40% of adults in the United States were obese (Emmerich, NCHS Data Brief, 2024). Obesity is associated with poor survival in adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) (Stock, Blood, 2019) (Shimony, Blood Advances, 2023). Poorer survival among patients with obesity is multifactorial. Obese patients experience increased treatment toxicities (hepatotoxicity, hyperglycemia, and thromboembolic events) translating into higher non-relapse mortality. Additionally, ALL treatment resistance during induction and maintenance phases, leading to primary induction failures and higher MRD detection rates in those who attain a remission, is seen in those with obesity. The biological basis of these clinical findings has been well described. Adipocytes (1) donate metabolic fuel in the form of asparagine, glutamine, and free fatty acids; (2) reduce chemotherapy-induced oxidative stress; and (3) spur proliferation. Additionally, adipocytes have been shown to protect lymphoblasts from anthracyclines and asparaginase. The Improve Diet and Exercise in ALL (IDEAL) Trial (Orgel, Blood Advances, 2022) showed that a caloric deficit, accomplished jointly by nutritional and exercise interventions with the end goal of minimizing fat mass gain and muscle loss, was feasible and may improve chemotherapy efficacy during induction in pediatric B-ALL patients. This trial, Nutrition and Exercise to Optimize Muscle and Adiposity in Adults with B-ALL (NEOMA, NCT06785324), aims to bring this therapeutic modality to the AYA ALL population. Study Design and Methods: NEOMA is a pilot interventional trial of nutrition and exercise in 15 AYA patients with B-ALL. Patients must be age>18 years-50 years, have Philadelphia chromosome negative (Ph (-)) ALL, and receive a pediatric-inspired induction regimen. Ineligibility criteria include BMI<18.5 kg/m2. The nutrition intervention targets a 10% caloric deficit calculated from each patient’s Basal Metabolic Rate (WHO/Schofield) utilizing a high protein (>25%), low fat (<25%), low glycemic index/high fiber (45-55%) diet. The study dietician meets with the patient on day of enrollment to go over the “menu” of dietary options, provide education, and re-assesses the patient every two days for adherence. The exercise intervention targets 200 minutes of moderate intensity physical activity weekly, as defined by Metabolic Equivalents (METs) of 3-6, made up of aerobic and resistance training activities tailored to the patient’s preference by working with the study physical therapist (PT). 200 minutes of moderate intensity physical activity achieves an additional 10% caloric deficit weekly. The 3-week NEOMA intervention is in the inpatient setting. The primary aim is to establish feasibility, adherence, and usability. NEOMA will be deemed feasible if >70% of patients eligible for enrollment consent to NEOMA. The dietary intervention will be deemed of acceptable adherence if >75% of patients are categorized as “adherent”, defined as >75% of the patient’s dietary assessments consistent with the prescribed diet. The exercise intervention will be deemed of acceptable adherence if >50% of patients are able to meet the exercise goal (200 minutes of 3-6 METs physical activity=600 MET-minutes minimum weekly goal) in 2 out of 3 weeks of induction therapy. Secondary outcomes include body composition and metabolomic changes, end of induction MRD status as assessed by ClonoSEQ® assay, and treatment toxicities. Metabolomics assessments are done on daily serum samples and pre- and post-intervention bone marrow aspirate utilizing a modified folch extraction to measure both lipids and polar metabolites on a dedicated LC-MS system. Changes in visceral adiposity and skeletal muscle are evaluated at the 1st lumbar spinal level from CT scans using the Data Analysis Facilitation Suite, version 3.6.0 (Voronoi Health Analytics Inc) to obtain automated body composition measurements. Current Progress: NEOMA opened on 5/12/2025 with an anticipated enrollment over 1 year. 2 patients have been approached for consent with 1 patient enrolling and 1 screen failure (Ph+). This is the first interventional study in AYAs with ALL aimed to decrease adiposity and improve muscle mass during induction therapy. If the NEOMA intervention is shown to be feasible, useable, and effective, the study would provide preliminary data to inform a randomized clinical trial of the intervention.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,001
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Essai non randomisé · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,005
Score d'incertitude au seuil0,016

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0010,001
Méta-épidémiologie (sens strict)0,0010,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0010,001
Science ouverte0,0000,001
Intégrité de la recherche0,0010,003
Charge utile insuffisante (le modèle a refusé de juger)0,0050,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,010
Tête enseignante GPT0,265
Écart entre enseignants0,255 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeEssai non randomisé
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2025
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetChildhood Cancer Survivors' Quality of Life→Travaux en français237 207→